title: Chronic thromboembolic pulmonary hypertension: Medical treatment.
abstract: Chronic thromboembolic pulmonary hypertension (CTEPH) is responsible for significant levels of morbidity and mortality. The estimated cumulative incidence of CTEPH is 2-4% among patients presenting with acute pulmonary thromboembolism. Currently, at the time of CTEPH diagnosis, 37.9% of the patients in an international registry were receiving at least one pulmonary arterial hypertension (PAH)-targeted therapy. Advanced medical therapy is considered in patients with inoperable disease, as a bridge to pulmonary endarterectomy or in those with persistent or recurrent pulmonary hypertension. PAH-specific medical therapies include endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogues. The present article will focus on recent developments in the pharmacological treatment of CTEPH.
authors.affiliation: Department of Pulmonary Medicine, Karadeniz Technical University School of Medicine, Trabzon, Turkey.
authors.forename: Savas
authors.initials: S
authors.lastname: Ozsu
authors.forename: Halit
authors.initials: H
authors.lastname: Cinarka
keywords: chronic thromboembolism; medical treatment; pulmonary hypertension